Karyopharm Therapeutics (KPTI)
0.42
+0.06 (16.67%)
Upcoming Events
Latest Headlines
Form 4 Karyopharm Therapeutics For: Oct 16 Filed by: Abate Kristin
October 19, 2026 4:03 PM - SEC Filing
Form 8-K Karyopharm Therapeutics For: Oct 13
October 14, 2026 7:30 AM - SEC Filing
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: ACORN BIOVENTURES, L.P.
October 8, 2026 10:27 AM - SEC Filing
Form 4 Karyopharm Therapeutics For: Oct 01 Filed by: Abate Kristin
October 2, 2026 4:02 PM - SEC Filing
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026 4:05 PM - PR NewsWire
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: ACORN BIOVENTURES, L.P.
September 25, 2026 2:19 PM - SEC Filing
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: ACORN BIOVENTURES, L.P.
September 25, 2026 10:57 AM - SEC Filing
Form 8-K Karyopharm Therapeutics For: Sep 17
September 18, 2026 4:06 PM - SEC Filing
Form 8-K Karyopharm Therapeutics For: Sep 10
September 11, 2026 7:45 AM - SEC Filing
Karyopharm files sNDA seeking FDA approval for myelofibrosis combo
August 31, 2026 7:32 AM - StreetInsider
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
August 14, 2026 4:49 PM - SEC Filing
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Commodore Capital LP
August 14, 2026 4:20 PM - SEC Filing
Form 10-Q Karyopharm Therapeutics For: Jun 30
August 13, 2026 7:41 AM - SEC Filing
Form 8-K Karyopharm Therapeutics For: Aug 13
August 13, 2026 7:38 AM - SEC Filing
Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
August 13, 2026 7:34 AM - StreetInsider
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
August 13, 2026 7:30 AM - PR NewsWire
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Adage Capital Management, L.P.
August 12, 2026 12:04 PM - SEC Filing
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: GOLDMAN SACHS GROUP INC
August 11, 2026 8:54 PM - SEC Filing
Increasing unusual call volume: KPTI ACB SHLD ABAT BW PBF UPWK TME TENX BMBL ARMK AS KOPN SES
August 11, 2026 9:55 AM - StreetInsider
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
August 10, 2026 7:30 AM - PR NewsWire
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026 4:05 PM - PR NewsWire
Karyopharm Therapeutics (KPTI) PT Lowered to $11 at Jefferies
July 31, 2026 10:31 AM - StreetInsider
Karyopharm Therapeutics (KPTI) PT Lowered to $7 at Piper Sandler
July 31, 2026 8:35 AM - StreetInsider
Form 8-K Karyopharm Therapeutics For: Jul 30
July 31, 2026 8:31 AM - SEC Filing
H.C. Wainwright Downgrades Karyopharm Therapeutics (KPTI) to Neutral
July 31, 2026 6:07 AM - StreetInsider
Baird Downgrades Karyopharm Therapeutics (KPTI) to Neutral
July 31, 2026 3:15 AM - StreetInsider
Form 4 Karyopharm Therapeutics For: Jul 28 Filed by: Poulton Stuart
July 30, 2026 4:42 PM - SEC Filing
Karyopharm to file myelofibrosis drug application in August 2026
July 30, 2026 4:08 PM - StreetInsider
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
July 30, 2026 4:06 PM - PR NewsWire
Karyopharm's endometrial cancer trial misses primary endpoint
July 30, 2026 4:05 PM - StreetInsider
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
July 30, 2026 4:05 PM - PR NewsWire
Form SCHEDULE 13G Karyopharm Therapeutics Filed by: BlackRock, Inc.
July 28, 2026 4:47 PM - SEC Filing
Full Article List
